Acute pain is a type of pain that comes on quickly but lasts a short amount of time. Journavx (jor-na-vix) was approved in 2025 and is the first non-opioid medicine in its class that is used to ...
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
A James Island pharmacist is looking to the future of pain management thanks to the Food and Drug Administration approving a ...
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
Journavx will likely follow the trajectory ... The drug was approved for up to two weeks of pain management. Suzetrigine is a sodium channel blocker that blocks a specific sodium channel called ...
Arbuckle claims, as industry executives often do, that his team has had fruitful conversations with these stakeholders, that they appreciate Journavx may fill a major gap in pain management.
In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated statistically significant reductions in acute surgical pain over 48 hours ...
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
The drug, called Journavx, is part of a broader effort by the Food and Drug Administration and healthcare providers to develop non-addictive pain management options. Journavx is the first in a ...
reinforcing CenExel's commitment to advancing pain management research and delivering high-quality clinical trial execution. "The approval of JOURNAVX represents a monumental step forward in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback